We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

India's First Drug EMR Could Set Off Litigation Wave, Industry Warns

Law360 (November 13, 2003, 12:00 AM EST) -- The grant of India's first exclusive marketing right (EMR) to Swiss drugmaker Novartis for its leukemia medicine Gilvec (imatinib mesylate) could set off a wave of patent litigation, the Economic Times of India reported.

Novartis' EMR grant, issued by the Controller General of Patents and Trademarks of India, blocks the duplication and sale of the drug by any other company for five years.

"We are in an uncharted territory and we are evaluating all our options carefully. We hope that the Indian government will ensure the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.